GKT137831: Dual NADPH Oxidase Nox1/Nox4 Inhibitor for Oxidative Stress Research

Executive Summary: GKT137831 (CAS 1218942-37-0, SKU B4763) is a small-molecule inhibitor that selectively targets NADPH oxidase isoforms Nox1 and Nox4, with Ki values of 140 nM and 110 nM, respectively, under cell-free assay conditions (ApexBio, product page). It suppresses hypoxia- and TGF-β1-induced ROS (H₂O₂) generation, cell proliferation, and profibrotic signaling in pulmonary vascular cells (Laleu 2010, doi:10.1021/jm100087s). In vivo, GKT137831 reduces hepatic fibrosis, diabetic atherosclerosis, and cardiac hypertrophy by inhibiting Akt/mTOR and NF-κB pathways (Jha 2017, doi:10.1038/s41598-017-03477-z). The compound is recommended at 0.1–20 μM for in vitro assays and 30–60 mg/kg/day (oral) in animal models (ApexBio datasheet). GKT137831 is provided by APExBIO for research use only.

Biological Rationale

Reactive oxygen species (ROS) are central mediators of oxidative stress and cellular signaling. NADPH oxidases (Nox enzymes) generate superoxide and H₂O₂ in response to growth factors, cytokines, and injury. Nox1 and Nox4 are highly expressed in vascular smooth muscle cells and endothelial cells, where they regulate cell proliferation, migration, and extracellular matrix remodeling (Sedeek 2013, PMC3763597). Overactivation of Nox1/Nox4 contributes to the pathogenesis of vascular remodeling, pulmonary hypertension, hepatic fibrosis, diabetic atherosclerosis, and cardiac hypertrophy. Targeted inhibition of these isoforms enables precise modulation of redox signaling for basic and translational research (Rewiring Redox Biology). This article extends prior coverage by providing a comprehensive, citation-dense guide to dosage, mechanisms, and pitfalls.

Mechanism of Action of GKT137831

GKT137831 is a competitive inhibitor of Nox1 and Nox4, blocking the electron transfer required for ROS generation. Its molecular structure enables selectivity against other Nox isoforms and unrelated oxidases (Laleu 2010, doi:10.1021/jm100087s). In pulmonary vascular cells, GKT137831 limits hypoxia-induced H₂O₂ release, proliferation, and TGF-β1 induction—key drivers of vascular remodeling (Jha 2017, doi:10.1038/s41598-017-03477-z). It also modulates downstream signaling pathways including Akt/mTOR, NF-κB, and PPARγ, further attenuating profibrotic and proinflammatory responses (ApexBio, product page). By reducing ROS at the source, GKT137831 allows for mechanistic dissection of redox-dependent processes in vitro and in vivo. Prior articles have focused on in vitro selectivity; here, we detail signaling specificity and model selection.

Evidence & Benchmarks

• GKT137831 inhibits Nox1 and Nox4 with Ki values of 140 nM and 110 nM, respectively, in cell-free enzyme assays (Laleu 2010, doi:10.1021/jm100087s).
• In human pulmonary artery endothelial and smooth muscle cells, GKT137831 at 1–10 μM reduces hypoxia-induced H₂O₂ generation by >70% within 24 hours (Jha 2017, doi:10.1038/s41598-017-03477-z).
• Oral administration (30–60 mg/kg/day) in rodent models attenuates hepatic fibrosis, diabetic atherosclerosis, and cardiac hypertrophy, with significant reduction in fibrotic markers, inflammatory cytokines, and vascular remodeling scores (Aoyama 2012, doi:10.1172/JCI60015).
• Downregulation of TGF-β1 and NF-κB signaling observed in GKT137831-treated animals, confirmed by immunoblotting and histology (Jha 2017, doi:10.1038/s41598-017-03477-z).
• GKT137831 is soluble at ≥39.5 mg/mL in DMSO and ≥2.96 mg/mL in ethanol (with warming/ultrasonication), but insoluble in water (ApexBio, product page).
• Experimental reproducibility is enhanced when using GKT137831 as a reference compound in oxidative stress and cell viability assays (Practical Solutions).

Applications, Limits & Misconceptions

GKT137831 facilitates multiple research applications:

• Dissection of redox signaling pathways in vascular, hepatic, and cardiac disease models.
• Attenuation of hypoxia-induced pulmonary vascular remodeling and cell proliferation assays.
• Preclinical evaluation of antifibrotic, anti-inflammatory, and antiremodeling strategies.
• Validation of NADPH oxidase as a therapeutic target in diabetic atherosclerosis and hepatic fibrosis.

Common Pitfalls or Misconceptions

• GKT137831 is not a pan-NADPH oxidase inhibitor; it does not significantly inhibit Nox2 or Nox5 at standard concentrations (Laleu 2010, doi:10.1021/jm100087s).
• The compound is insoluble in water; improper solvent use can lead to precipitation and loss of activity (ApexBio, product page).
• GKT137831 is strictly for research use and not for clinical application or diagnostic purposes (ApexBio).
• Long-term storage of GKT137831 solutions (especially in DMSO) at room temperature leads to degradation; storage at -20°C is required (ApexBio).
• It does not directly scavenge ROS; its effects are mediated by upstream enzyme inhibition, not chemical antioxidant activity.

Workflow Integration & Parameters

For cell-based assays, GKT137831 is typically used at 0.1–20 μM, depending on cell type and endpoint. Freshly prepared DMSO or ethanol (with warming/ultrasonication) stocks are recommended. In animal studies, oral gavage or intragastric injection at 30–60 mg/kg/day is standard. Solutions should not be stored long-term. Incorporating GKT137831 as a control or reference standard improves reproducibility in oxidative stress workflows, as demonstrated in recent scenario-based guides, which this article updates with new mechanistic benchmarks and solvent recommendations. APExBIO supplies GKT137831 as a research-use-only reagent, ensuring batch-to-batch consistency and validated performance.

Conclusion & Outlook

GKT137831 is a validated, selective dual NADPH oxidase Nox1/Nox4 inhibitor that enables robust, reproducible interrogation of oxidative stress pathways in vascular, hepatic, and cardiac models. Its molecular selectivity, well-documented benchmarks, and workflow versatility make it a cornerstone for redox biology research. For authoritative details and ordering, see the GKT137831 product page from APExBIO. As redox modulation emerges as a therapeutic frontier (Yang 2025, doi:10.1126/sciadv.adx6587), GKT137831 will continue to underpin translational advances in oxidative stress, fibrosis, and vascular remodeling research.